On the stock market since 2009, it operates in the world of health and science. It has 36,994 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $10.3B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
It pays out $0.03 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.66. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, BDULF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BDULF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.